| First Author | Griffett K | Year | 2020 |
| Journal | PLoS One | Volume | 15 |
| Issue | 10 | Pages | e0236000 |
| PubMed ID | 33002003 | Mgi Jnum | J:296395 |
| Mgi Id | MGI:6466605 | Doi | 10.1371/journal.pone.0236000 |
| Citation | Griffett K, et al. (2020) REV-ERB agonism improves liver pathology in a mouse model of NASH. PLoS One 15(10):e0236000 |
| abstractText | Non-alcoholic fatty liver disease (NAFLD) affects a significant number of people worldwide and currently there are no pharmacological treatments. NAFLD often presents with obesity, insulin resistance, and in some cases cardiovascular diseases. There is a clear need for treatment options to alleviate this disease since it often progresses to much more the much more severe non-alcoholic steatohepatitis (NASH). The REV-ERB nuclear receptor is a transcriptional repressor that regulates physiological processes involved in the development of NAFLD including lipogenesis and inflammation. We hypothesized that pharmacologically activating REV-ERB would suppress the progression of fatty liver in a mouse model of NASH. Using REV-ERB agonist SR9009 in a mouse NASH model, we demonstrate the beneficial effects of REV-ERB activation that led to an overall improvement of hepatic health by suppressing hepatic fibrosis and inflammatory response. |
